Premium
Luteinizing Hormone‐Releasing Hormone (LH‐RH) Treatment for Inducing Clomiphene Response in Anovulatory Patients with Hypogonadotropic Hypogonadism
Author(s) -
Kotsuji Fumikazu,
Kitaguchi Mitsue,
Okamura Yutaka,
Tojo Shimpei
Publication year - 1982
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1982.tb00559.x
Subject(s) - luteinizing hormone , gonadotropin , hypogonadotropic hypogonadism , medicine , endocrinology , basal (medicine) , clomifene , progestin , follicle stimulating hormone , gonadotropin releasing hormone , hormone , ovulation , ovulation induction , insulin
LH‐RH was administered to anovulatory patients with hypogonadotropic hypogonadism to convert them to clomiphene responders. This synthetic decapeptide was injected intramuscularly in doses of 100 μ g twice a week for six weeks. Diagnostic tests of progestin, LH‐RH and gonadotropin were performed before and after LH‐RH treatment. Seven out of nine patients became clomiphene or clomiphene‐hCG responders after one course of treatment. One patient became a clomiphene‐hCG responder after one additional course of treatment. One patient with hypothyroidism did not respond to clomiphene citrate with two courses of treatment. The results of the progestin test and gonadotropin test and the basal E 2 levels after this treatment were correlated with the ovulatory response to clomiphene therapy or to clomiphene‐hCG therapy after LH‐RH treatment. But basal gonadotropin levels and the mode of gonadotropin responses of the LH‐RH test were not necessarily correlated with the ovulatory response to clomiphene or clomiphene‐hCG therapy after LH‐RH treatment.